ABSI
Price
$8.82
Change
+$0.02 (+0.23%)
Updated
Sep 4 closing price
Capitalization
1.51B
73 days until earnings call
Intraday BUY SELL Signals
RXRX
Price
$3.63
Change
+$0.19 (+5.52%)
Updated
Sep 4 closing price
Capitalization
1.97B
67 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABSI vs RXRX

ABSI vs RXRX Comparison Chart in %
View a ticker or compare two or three
VS
ABSI vs. RXRX commentary
Sep 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABSI is a Hold and RXRX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 05, 2026
Stock price -- (ABSI: $8.82 vs. RXRX: $3.63)
Brand notoriety: ABSI and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABSI: 62% vs. RXRX: 144%
Market capitalization -- ABSI: $1.51B vs. RXRX: $1.97B
ABSI [@Biotechnology] is valued at $1.51B. RXRX’s [@Biotechnology] market capitalization is $1.97B. The market cap for tickers in the [@Biotechnology] industry ranges from $138.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.33B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABSI’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).

  • ABSI’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, RXRX is a better buy in the long-term than ABSI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABSI’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 6 bullish TA indicator(s).

  • ABSI’s TA Score: 4 bullish, 5 bearish.
  • RXRX’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than ABSI.

Price Growth

ABSI (@Biotechnology) experienced а +1.26% price change this week, while RXRX (@Biotechnology) price change was +8.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.22%. For the same industry, the average monthly price growth was +5.23%, and the average quarterly price growth was +2396.59%.

Reported Earning Dates

ABSI is expected to report earnings on Nov 17, 2026.

RXRX is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-0.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($1.97B) has a higher market cap than ABSI($1.51B). ABSI YTD gains are higher at: 152.722 vs. RXRX (-11.247). ABSI has higher annual earnings (EBITDA): -106.8M vs. RXRX (-478.66M). RXRX has more cash in the bank: 654M vs. ABSI (126M). ABSI has less debt than RXRX: ABSI (4.42M) vs RXRX (72.4M). RXRX has higher revenues than ABSI: RXRX (65.7M) vs ABSI (1.84M).
ABSIRXRXABSI / RXRX
Capitalization1.51B1.97B77%
EBITDA-106.8M-478.66M22%
Gain YTD152.722-11.247-1,358%
P/E RatioN/AN/A-
Revenue1.84M65.7M3%
Total Cash126M654M19%
Total Debt4.42M72.4M6%
TECHNICAL ANALYSIS
Technical Analysis
ABSIRXRX
RSI
ODDS (%)
Bullish Trend 6 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 25 days ago
90%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 9 days ago
87%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
ABSI
Daily Signal:
Gain/Loss:
RXRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FTXL227.857.91
+3.60%
First Trust Nasdaq Semiconductor ETF
NACP60.500.13
+0.22%
Impact Shares NAACP Minority Empwrmt ETF
JLQD40.190.01
+0.03%
Janus Henderson Corporate Bond ETF
QUSA17.91-0.02
-0.11%
Vistashares Target 15 Usa Quality Income ETF
ROE43.52-0.10
-0.23%
Astoria US Equal Weight Quality KingsETF